Paul Hud­son and Tri­alSpark's mu­tu­al de­sire to speed up de­vel­op­ment con­verges in three-year, six-drug goal

A uni­corn start­up that orig­i­nal­ly set out to has­ten clin­i­cal stud­ies for bio­phar­ma part­ners dug fur­ther in­to its re­vised path of in­ter­nal drug de­vel­op­ment by link­ing arms with Sanofi in a pact that the biotech’s CEO said orig­i­nat­ed from the top.

Tri­alSpark and the Big Phar­ma on Tues­day com­mit­ted to in-li­cens­ing and/or ac­quir­ing six Phase II/Phase III drugs with­in the next three years.

“I’ve known Paul Hud­son for a while and we were dis­cussing the op­por­tu­ni­ty to re­al­ly re-imag­ine a lot of dif­fer­ent parts of phar­ma,” Tri­alSpark CEO Ben­jamine Liu told End­points News, “and one of the things that we dis­cussed was this op­por­tu­ni­ty to ac­cel­er­ate the de­vel­op­ment of new med­i­cines in mu­tu­al ar­eas of in­ter­est.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER